News Headlines Article

Genentech aims to extend Avastin to cervical cancer
San Francisco Business Times

Regulators will clear a path for review of Genentech Inc.’s Avastin — one of the world’s best-selling cancer drugs — as the company tries to extend the drug’s use to certain types of cervical cancer. South San Francisco-based Genentech, the U.S. biotech unit of Swiss drug maker Roche, said the Food and Drug Administration granted priority review to Avastin plus chemotherapy to treat women with persistent, recurring or metastatic cervical cancer.